



American Society for Gastrointestinal Endoscopy guideline on gastrostomy feeding tubes: summary and recommendations

Prepared by: THE ASGE STANDARDS OF PRACTICE COMMITTEE

Divyanshoo Rai Kohli, MD, FASGE, FACG,^{1,*} Wasif M. Abidi, MD, PhD,^{2,*} Natalie Cosgrove, MD,^{3,*} Jorge D. Machicado, MD, MPH,⁴ Madhav Desai, MD, MPH,⁵ Nauzer Forbes, MD, MSc, FASGE,⁶ Neil B. Marya, MD,⁷ Nikhil R. Thiruvengadam, MD,⁸ Nirav C. Thosani, MD, MHA,⁵ Omeed Alipour, MD,⁹ Saowanee Ngamruengphong, MD, FASGE,¹⁰ Sherif E. Elhanafi, MD,¹¹ Sunil G. Sheth, MD, FASGE,¹² Wenly Ruan, MD,¹³ John C. Fang, MD,¹⁴ Stephen A. McClave, MD, FASGE,¹⁵ Rodrick C. Zvavanjanja, MD, MSc, FRCR(UK), FSIR, DABR(DR/VIR),¹⁶ Amir Y. Kamel, PharmD, BCNSP,^{17,18} Bashar J. Qumseya, MD, MPH, FASGE, ASGE Standards of Practice Committee Chair¹⁷

This document was reviewed and approved by the Governing Board of the American Society for Gastrointestinal Endoscopy.

This clinical practice guideline from the American Society for Gastrointestinal Endoscopy (ASGE) provides an evidence-based approach for strategies to manage endoscopically placed gastrostomy tubes. This document was developed using the Grading of Recommendations Assessment, Development and Evaluation framework. The guideline addresses the utility of PEG versus interventional radiology-guided gastrostomy (IR-G), need for withholding antiplatelet and anticoagulant medications before PEG tube placement, appropriate timing to initiate tube feeding after PEG, and selection of the appropriate technique of gastrostomy in patients with malignant dysphagia. In patients needing enteral access, the ASGE suggests PEG as the preferred technique for initial gastrostomy over IR-G. The ASGE recommends that tube feeding can be safely started within 4 hours of gastrostomy. The ASGE suggests that PEG can be performed without withholding antiplatelet medications. The ASGE suggests that the periprocedural management of anticoagulants should be based on a multidisciplinary discussion regarding the risk of bleeding versus cardiovascular events. In patients with malignant dysphagia, either transoral “pull” PEG or direct PEG can be performed for initial enteral access. (Gastrointest Endosc 2025;101:25-35.)

This guideline document was prepared by the Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy using the best available scientific evidence and considering a multitude of variables including but not limited to adverse events, patient values, and cost implications. The purpose of these guidelines is to provide the best practice recommendations that may help standardize patient care, improve patient outcomes, and reduce variability in practice. We recognize that clinical decision-making is complex. Guidelines therefore are not a substitute for a clinician's judgment. Such judgements may, at times, seem contradictory to our guidance because of many factors that are impossible to fully consider by guideline developers. Any clinical decisions should be based on the clinician's experience, local expertise, resource availability, and patient values and preferences. This document is not a rule and should not be construed as establishing a legal standard of care or as encouraging,

advocating for, mandating, or discouraging any particular treatment. Our guidelines should not be used in support of medical complaints, legal proceedings, and/or litigation as they were not designed for this purpose.

Enteral access for long-term nutrition may be required for patients with dysphagia or inadequate intake of food. In such patients with an intact and functional GI tract, a gastrostomy is the preferred means to facilitate enteral nutrition.^{1,2} Although the percutaneous insertion of a feeding tube is a safe and effective technique,³ there are uncertainties regarding the most effective approach for gastrostomy tube placement, managing patients requiring gastrostomy tube placement, and providing guidance for clinical decision-making.

For initial enteral access, either an endoscopic or radiologic technique can be used to perform a gastrostomy. Conventionally, a PEG entails visualization of the gastric lumen, and the

procedure is performed with the patient under moderate sedation or propofol-based anesthesia without the need for fluoroscopy or contrast. Radiologic techniques typically require minimal sedation of the patient, are performed with fluoroscopy, and require nasogastric tube access and use of iodinated contrast media.⁴ The optimal technique and comparative benefits of either technique remain under investigation.

Questions regarding the management of antithrombotic medications routinely come up before performing a gastrostomy, and these medications are often withheld to minimize the risk of bleeding. PEG is categorized as a higher risk procedure for bleeding when patients are on anticoagulants or dual-antiplatelet therapy.⁵ Withholding antiplatelet therapy for PEG tube placement is risky in patients with cardiovascular or cerebrovascular comorbidities. More recent data have further clarified the risk and questioned the utility of withholding antiplatelet therapy in patients undergoing PEG.⁶ Hence, existing algorithms for the management of antithrombotic therapy need to be re-evaluated.

Initiation of tube feeding is often delayed after PEG tube placement, although data to support this practice are limited. Finally, in a subset of patients with upper GI tract malignancy, there is a risk of implantation metastasis with a gastrostomy. In such patients, guidance is limited on the safest and most appropriate technique for enteral access. Therefore, the aim of this guideline is to provide high-quality, clinically relevant, evidence-based recommendations for the management of gastrostomies in patients requiring long-term enteral access.

METHODS

This document was prepared by the Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE) and was conceptualized and conducted according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.⁷⁻⁹ Evidence was presented to a panel of experts including an interventional radiologist, nutrition support specialist, and gastroenterologists with expertise in managing gastrostomy feeding tubes. A patient advocate was also included. All panel members were required to disclose potential financial and intellectual conflicts of interest, which were addressed according to ASGE policies. We took into consideration the certainty of the evidence, benefits and harms of different management options, feasibility, patient values and preferences, resource utilization, cost-effectiveness, and health equity in developing these recommendations. The final wording of the recommendations were approved by all members of the panel and the ASGE governing board. Stronger recommendations are stated as “we recommend...,” whereas conditional recommendations are indicated by “we suggest...” based on the GRADE framework. Further details of the methodology used for this guideline including

systematic reviews, evidence profile, and results from all meta-analyses are presented separately in the accompanying document on methodology and review of evidence.

This guideline addressed the following clinical questions following the population, intervention, comparison, outcome format using the GRADE methodology:

1. In patients with normal foregut anatomy needing initial enteral access, is PEG or interventional radiology-guided percutaneous gastrostomy (IR-G) the preferred modality?
2. In patients undergoing PEG, should antiplatelet or anti-coagulant agents be held before the procedure?
3. In patients who undergo PEG tube placement, should tube feeds be initiated early or be intentionally delayed?
4. In patients with malignant dysphagia requiring gastrostomy placement, is transoral pull PEG or transcutaneous direct gastrostomy the preferred modality to reduce the risk of implantation metastasis?

SUMMARY OF RECOMMENDATIONS

Details of our literature search, data analyses, pooled-effects estimates, evidence profiles, forest plots, and panel deliberation for each outcome can be found in the accompanying document subtitled “Methodology and review of evidence” published in *VideoGIE*. A summary of our final recommendations for management of patients with gastrostomy is listed in [Table 1](#).

Question 1. In patients with normal foregut anatomy needing initial enteral access, is PEG or IR-G the preferred modality?

Recommendation 1. In patients with normal foregut anatomy requiring enteral access, the ASGE suggests PEG over IR-G as the initial approach for gastrostomy.

(Conditional recommendation, low quality of evidence)

Summary of the evidence

For this question, a systematic review of published literature comparing PEG and IR-G as the initial intervention for enteral access was performed. Outcomes of interest included all-cause mortality at 30 days, malfunction of feeding tube, colon perforation, peritonitis, technical failure, bleeding, and aspiration. Studies assessing outcomes of percutaneous endoscopic jejunostomy, PEG or IR-G with jejunal extension, and feeding tube exchange through pre-existing gastrostomies were excluded.

A recently published high-quality systematic review and meta-analysis that assessed 33 studies comparing outcomes in 275,117 patients who underwent PEG and 192,691 patients who underwent IR-G was identified and updated.¹⁰ While updating that meta-analysis,¹⁰ 2 other studies that met selection criteria were also included.^{11,12} The meta-

TABLE 1. Summary of recommendations and best practice advice

Recommendation	Best practice advice	Strength of recommendation	Quality of evidence
1. In patients with normal foregut anatomy requiring enteral access, the ASGE suggests PEG over interventional radiology–guided gastrostomy as the initial approach for gastrostomy.	<ul style="list-style-type: none"> • Transillumination, 1-to-1 indentation, and safe-track needle technique with air aspiration should be performed during PEG to reduce risk of colon perforation. • Prophylactic antibiotics (eg, cefazolin) should be administered at the time of initial gastrostomy to reduce risk of infection. 	Conditional	Low
2a. In patients on antiplatelet drugs, including dual-antiplatelet therapy, who need to undergo PEG tube placement, the ASGE suggests against routine withholding of antiplatelet drugs. 2b. In patients on anticoagulants who need to undergo PEG tube placement, the ASGE suggests that the periprocedural management of anticoagulants should be based on a multidisciplinary discussion including the patient, weighing the risk of bleeding vs cardiovascular events.	<ul style="list-style-type: none"> • PEG tube placement may be performed while patients are on antiplatelet medications. • In patients on antithrombotic medications who have restrictions to blood transfusions (antibodies or religious beliefs) or are at high risk of bleeding, the ASGE suggests that continuation of antiplatelet and anticoagulation medications should be based on a multidisciplinary discussion with the team and patient • Tightening the bumper of the PEG tube for 24 hours and then loosening it may be considered to tamponade against potential bleeding. However, data to support the practice are limited, and care should be taken to avoid excessive tightening to minimize the risk of a buried bumper. 	Conditional	Very low
3. In patients who undergo PEG tube placement, the ASGE recommends that PEG tubes may be used for feeding early (within 4 h) over routine delays in initiation.	<ul style="list-style-type: none"> • In the absence of clinical contraindications, medications may be administered through the PEG tube immediately after placement. • Routine measurement of gastric residual volume is not indicated. 	Strong	Moderate (for randomized controlled trials) Low (for all studies)
4. In patients with malignant dysphagia requiring gastrostomy tube placement, the ASGE suggests either transoral pull PEG or transcutaneous direct PEG.	<ul style="list-style-type: none"> • Patients should be counseled about the risk of implantation metastasis during the informed consent process. • The gastrostomy site should be periodically examined to assess for implantation metastasis. 	Conditional	Very low

ASGE, American Society for Gastrointestinal Endoscopy.

analysis also included 1 randomized clinical trial¹² and 3 large, nationwide studies that used administrative databases to identify patients and compare outcomes.¹³⁻¹⁵ These 3 studies were excluded from the initial analysis and used as supportive evidence after an initial analysis had been completed.

When compared with IR-G, PEG was associated with a lower all-cause mortality at 30 days (20 studies^{4,16-34}; odds ratio [OR], .57; 95% confidence interval [CI], .37-.87; $I^2 = 30.3\%$, $P = .01$) and lower incidence of tube malfunction (20 studies^{11,18-21,23,24,27-32,35-41}; OR, .51; 95% CI, .28-.92; $I^2 = 84\%$, $P = .02$). PEG and IR-G had comparable incidences of significant postprocedural bleeding (15 studies^{4,12,18,19,21,24,25,29,32-38}; OR, .8; 95% CI, .31-2.0; $I^2 = 0$, $P = .59$), technical failure (14 studies^{4,16,17,24,25,29-31,33,36,38,42-44}; OR, 2.52; 95% CI, .92-6.89; $I^2 = 61\%$, $P = .06$), peristomal infection (21 studies^{11,19-21,24-30,32-41}; OR, .92; 95% CI, .65-1.29; $I^2 = 24.5\%$, $P = .63$), and aspiration pneumonia

(9 studies^{4,21,25,29,30,32,33,37}, OR, .58; 95% CI, .28-1.21; $I^2 = 0$, $P = .11$).

Colon perforation and peritonitis are critical but uncommon adverse outcomes and are unlikely to be detected in underpowered, retrospective, single-center studies with small sample sizes. Hence, the panel reviewed the data from the recently published meta-analysis¹⁰ that included 3 studies which used large, nationally representative, administrative databases.¹³⁻¹⁵ Compared with IR-G, PEG was associated with lower odds of colon perforation (OR, .6; 95% CI, .49-.75; $I^2 = 17\%$, $P = .008$) and peritonitis (OR, .71; 95% CI, .63-.81; $I^2 = 0$, $P < .001$). Furthermore, when considering the evidence from the administrative databases,¹³⁻¹⁵ PEG was associated with lower odds of all-cause 30-day mortality (OR, .73; 95% CI, .58-.93; $I^2 = 50\%$, $P = .01$) and tube malfunction (OR, .56; 95% CI, .33-.95; $I^2 = 95\%$, $P = .03$).

No studies directly assessed cost or cost-effectiveness. No specific concerns were related to equity because IR-G

and PEG are both invasive procedures that are frequently performed at large and small community hospitals. Based on the GRADE methodology, the evidence was rated as low quality. Considering the above data and given the lower risk of all-cause mortality and tube malfunction, the panel made a conditional recommendation for PEG compared with IR-G.

Discussion

The interventional radiologist on the panel noted that IR-G feeding tubes are typically of a smaller diameter (12F-18F) that predisposes them to tube-related malfunction, including clogging and need for readjustment. The difference in malfunction may also partially be explained by the inflatable balloon system for the internal bolster on the IR-G tube versus the fixed mushroom internal bolster on the PEG tube. Further, the interventional radiologist noted that there has been considerable progress and advancement in the techniques of IR-G including the use of ultrasound guidance to identify structures in the planned needle access tract, use of coned-beam CT fluoroscopy with enhanced needle guidance, “I-guide” technology in challenging colonic interposition cases, and CT-guided gastrostomy tube placement, which may reduce the risk of adverse outcomes and mortality; however, outcomes data for these techniques are currently not available. The patient advocate on the panel also noted their own experience with the need for frequent replacement and higher incidence of tube malfunction with IR-G.

The panel noted that the risk of colon perforation with PEG can be mitigated by using endoscopic techniques to detect the presence of air-containing viscus between the anterior gastric wall and the abdomen. Transillumination, 1-to-1 indentation, and a safe-track needle technique (simultaneous aspiration of air and visualization of the needle within the stomach) must be performed to reduce the risk of colon perforation.^{1,45}

To minimize the risk of peristomal infection, current guidelines from the ASGE and the Society of Interventional Radiology recommend that prophylactic antibiotics should be administered at the time of gastrostomy,^{46,47} which was supported by this panel. Cefazolin is a frequently used antibiotic because it can be administered as a single intravenous dose and provides adequate broad-spectrum coverage.⁴⁸ It is typically administered at the time of the procedure or 30 minutes before the procedure.

Based on the above evidence and panel deliberations, the ASGE suggests PEG over IR-G as the modality of choice for initial enteral access. The panel noted that in institutions where IR-G is frequently performed or PEG is unavailable, IR-G can be considered an appropriate method for enteral access.

Question 2. In patients undergoing PEG, should antiplatelet or anticoagulant agents be held before the procedure?

Recommendation 2a. For patients on antiplatelet agents, including dual-antiplatelet therapy, who need to undergo PEG tube placement, the ASGE suggests against routine withholding of antiplatelet agents.

(Conditional recommendation, very low quality of evidence)

Recommendation 2b. In patients on anticoagulants who need to undergo PEG tube placement, the ASGE suggests the periprocedural management of anticoagulants should be based on a multidisciplinary discussion including the patient regarding the risk of bleeding versus cardiovascular events.

(Conditional recommendation, very low quality of evidence)

Summary of the evidence

A systematic review of published literature comparing PEG tube placement with or without antithrombotic medications was performed. Outcomes of interest were bleeding, mortality, risk of cardiovascular events, adverse events, blood product transfusions, and cost. Studies assessing outcomes of percutaneous endoscopic jejunostomy, PEG with jejunal extension or IR-G with jejunal extension, feeding tube exchange through pre-existing gastrostomies, or pediatric patients were excluded. Noncomparative studies were also excluded.

Only 1 study was identified that specifically compared outcomes after holding antithrombotic medications or continuing them at the time of feeding tube placement.⁴⁹ Because this was insufficient to make conclusions, further supportive evidence was obtained by including studies evaluating patients on any antithrombotic medication in the periprocedural period versus antithrombotic-naïve patients. Five retrospective cohort studies were identified, from which patient-level data were extracted on clinically significant bleeding.^{6,49-52} No usable data were available on other outcomes of interest, including mortality, risk of cardiovascular events, overall adverse events, transfusions, hospitalization, and cost. Very limited data were available on novel oral anticoagulants, and hence these were not included in the current guideline.

The definition of bleeding varied between different studies. Only 1 study stratified their data specifically on PEG-related bleeding. However, all studies reported

“significant bleeding,” defined as some variation of requiring endoscopic intervention, transfusion requirements, hemoglobin drop of ≥ 2 g/dL, or clinical signs of active bleeding.

The prevalence of bleeding did not vary when comparing patients taking antiplatelet drugs with those not taking antiplatelet drugs. Specifically, compared with patients not on aspirin, those on aspirin did not have a significant increase in bleeding (4 studies^{6,50-52}; OR, 1.39; 95% CI, .56-3.44; $P = .32$). Similarly, patients on clopidogrel did not have an increased rate of bleeding compared with patients not on clopidogrel (4 studies^{6,50-52}; OR, 1.26; 95% CI, .18-8.81; $P = .72$). Data on patients on dual-antiplatelet therapy were also extracted and no increase in bleeding was found, although only 2 studies reported patient-level data^{6,50} (OR, .75; 95% CI, .16-3.59; $P = .25$). The rate of bleeding for patients on compared with not on anticoagulation medications (therapeutic heparin or warfarin) also did not differ, although data were available from only 2 studies^{6,50} (OR, 1.56; 95% CI, .00-853.51; $P = .53$).

Discussion

Although the general practice in many centers is to hold antithrombotic medications, holding these medications is not feasible in some patients (ie, patients with recent ischemic stroke). The data reviewed, despite low quality, showed a very low risk of bleeding if patients continue antithrombotic medications. The panel noted that withholding antithrombotic medications could result in harm, particularly an increased risk of cardiovascular events.⁵³ Other unintended consequences may include delaying PEG tube placement, longer duration of nasogastric feeds, longer length of hospital stay, and delays in transfer to long-term acute care facilities. Furthermore, the bleeding events that were noted in the studies were non-life-threatening and generally easy to treat. Feedback was also elicited from the patient representative, who preferred bleeding over any risk of stroke or cardiovascular adverse event.

The data were limited given the low number of studies and the low event rates. This is particularly apparent in the wide OR in patients given anticoagulation drugs during their hospitalization, such that imprecision was rated very serious. Based on these data and the panel's deliberation, patients on antiplatelet and anticoagulation medications are treated differently. The ASGE suggests against routine withholding of antiplatelet drugs, including dual-antiplatelet therapy, in patients who need to undergo PEG tube placement. Additionally, the ASGE suggests that the periprocedural management of anticoagulants should be based on a multidisciplinary discussion, which should include the patient and their representatives, regarding the risk of bleeding from continuing antiplatelet and/or anticoagulation medications compared with the risk of cardiovascular adverse events from withholding such med-

ications (cerebrovascular accident, myocardial infarction, pulmonary embolus, etc).

Question 3. In patients who undergo PEG tube placement, should tube feeds be initiated early or be intentionally delayed?

Recommendation 3. In patients who undergo PEG tube placement, the ASGE recommends that PEG tubes may be used for feeding early (within 4 hours) over routine delays in initiation.

(Strong recommendation, low to moderate quality of evidence)

Summary of the evidence

For this question, a systematic review of the published literature comparing intentionally delayed versus early tube feed initiation after PEG tube placement was performed. Outcomes of interest were all-cause mortality at 30 days, short-term mortality (<72 hours), adverse events, vomiting, aspiration, peristomal leak, wound infection, and PEG site stomatitis. Noncomparative studies and studies assessing outcomes of percutaneous endoscopic jejunostomy, PEG with jejunal extension or IR-G with jejunal extension, feeding tube exchange through pre-existing gastrostomies, or examining pediatric patients were excluded.

We identified 4 randomized controlled trials (RCTs)⁵⁴⁻⁵⁷ and 4 non-randomized controlled comparative studies⁵⁸⁻⁶¹ for a total of 1120 patients. The definitions of early and delayed feeding varied across the studies. For our meta-analysis, we defined the initiation of early tube feed as at or before 4 hours after PEG tube placement and delayed initiation as over 4 hours after PEG tube placement. Outcomes were measured for both the RCTs alone and for the RCTs and non-RCTs combined.

All-cause mortality at 30 days was similar based on 2 RCTs^{54,56}: 23.3% for delayed versus 24.6% for early initiation (relative risk [RR], .93; 95% CI, .06-14.00; $P = .79$, $I^2 = 0\%$). When we additionally included 3 observational studies,^{54,56,59-61} these values were 9.3% versus 12% for delayed versus early initiation (OR, .83; 95% CI, .51-1.35; $P = .45$, $I^2 = 0\%$).

Short-term (<72 hours) mortality was also similar between early and delayed feeding in RCTs (6.7% vs 3.3%; RR, 1.78; 95% CI, .03-95.63; $P = .31$, $I^2 = 0\%$)^{54,56} and all studies (1.3% vs 1.6% for delayed versus early; OR, 1.06; 95% CI, .24-4.8; $P = .94$, $I^2 = 8\%$)^{54,56,59}. Four RCTs⁵⁴⁻⁵⁷ showed no difference in the overall adverse event rate (12.4% vs 12.4%; RR, 1.02; 95% CI, .23-4.47; $P = .96$, $I^2 = 25\%$). This was also true when combining observational studies⁵⁴⁻⁶¹ (15.4% vs 18.4% for delayed versus early feeding; OR, .97; 95% CI, .69-1.35; $P = .85$, $I^2 = 0\%$).

Regarding specific adverse events, there was no difference in vomiting in either the RCT data^{54,56} (8.3% vs 6.6%; RR, 1.30; 95% CI, .00-1819.1; $P = .72$, $I^2 = 0\%$) or for all studies combined^{54,55,57,59,60} (6.6% vs 4.6% delayed vs early feeding; OR, 1.42; 95% CI, .73-2.77; $P = .3$, $I^2 = 0\%$). Only 4 aspiration events were reported for all studies,^{55-57,59-61} all of which occurred in the delayed feeding group (.8% vs 0%; OR, 4.53; 95% CI, .73-28.06; $P = .1$, $I^2 = 0\%$). Although more peristomal leaks were noted in the early feeding group for all studies^{54,56,58-61} (2.8% vs 1%), this difference was small and not statistically significant (OR, .5; 95% CI, .16-1.59; $P = .24$, $I^2 = 3\%$). Rates of wound infection were also similar at 6% versus 4.2% (RR, 1.34; 95% CI, .0-304,188; $P = .81$, $I^2 = 8\%$) for the RCTs alone^{56,57} and 3.0% versus 3.3% for delayed versus early feeding (OR, 1.04; 95% CI, .46-2.34; $P = .93$, $I^2 = 0\%$) for combined studies.⁵⁶⁻⁶¹ A nonsignificant increase in stomatitis rates was noted for the early versus delayed feeding groups (4.9% vs 0%; RR, .26; 95% CI, .01-9.04; $P = .8$, $I^2 = 0\%$) when including only the RCTs^{54,56}; however, no difference was seen for the combined studies^{54,56,58,59,61} (1.9% delayed vs 1.4% early; OR, .9; 95% CI, .15-5.51; $P = .10$, $I^2 = 49\%$).

Discussion

There is a misconception that delayed initiation of tube feeds allows the stoma site to heal before tube feed initiation. However, the stoma site likely takes at least several weeks to heal completely.⁶¹ Another concern with early tube feed initiation has been that gastric wall puncture during PEG tube placement may transiently decrease gastric motility, resulting in increased gastric residual volume.⁵⁴ Although several studies included in our analysis reported gastric residual volume as an outcome, gastric residual volume measurement and definition of high gastric residuals are not standardized and vary between studies. Routine measurement of gastric residuals is also of unclear clinical significance and may lead to unnecessary tube feed discontinuation.⁶²⁻⁶⁵ Additionally, the omission of gastric residual monitoring results in increased enteral nutrition provision with reduced prokinetic use and GI adverse events.⁶⁶ Based on the available evidence, the panel agreed that routine gastric residual measurement is not indicated.

No studies compared cost-effectiveness, time to reach goal tube feed rate, or length of hospital stay. However, earlier tube feed initiation may theoretically allow patients to reach goal rates more quickly, resulting in decreased hospitalization length and reduced healthcare cost. The panel noted that the difference in nutritional status is likely clinically insignificant between early versus delayed tube feed initiation, although no studies reported this. Our patient advocate emphasized a desire to have tube feeding initiated as soon as possible to not delay or interrupt nutrition therapy and was reassured that there were no increased adverse events noted for earlier tube feed initia-

tion. The expert panel also noted a theoretical benefit of reducing the risk of ileus with earlier tube feed.

Overall, the evidence was of moderate quality. Given the lack of significant difference in outcomes between the early and delayed feeding groups, the theoretical benefits of earlier tube feed initiation, and the patient value assessment, the panel made a recommendation for early (within 4 hours) versus intentionally delayed tube feed initiation after PEG tube placement. The panel noted that initiation of early tube feeding after PEG tube placement may not be clinically appropriate in certain situations, including severe ileus, obstruction, or bowel ischemia. Early initiation of tube feeding may not always be feasible because of logistic delays. The panel noted that in most cases, medications may be given immediately through the PEG tube after placement, unless there are contraindications to enteral medications.

Question 4. In patients with malignant dysphagia requiring gastrostomy placement, is transoral pull PEG or transcutaneous direct gastrostomy the preferred modality to reduce the risk of implantation metastasis?

Recommendation 4. In patients with malignant dysphagia requiring gastrostomy placement, the ASGE suggests either a transoral pull PEG or transcutaneous direct PEG or IR-G.

(Conditional recommendation, very low quality of evidence)

Summary of the evidence

For this question, a systematic review of the published literature was performed. Outcomes of interest included the incidence of implantation metastasis and comparative success of direct PEG versus other modalities. A systematic review and meta-analysis from Siu et al⁶⁷ was reviewed. This meta-analysis was updated, and case reports were excluded from our final analysis. No studies directly compared transcutaneous direct PEG with transoral pull PEG in patients with malignant dysphagia. The incidence of implantation metastasis based on 11 observational retrospective studies^{11,23,68-76} was .6% with transoral pull PEG versus .07% with direct gastrostomy (transcutaneous direct PEG and IR-G) (OR, 3.34; 95% CI, .36-30.70; $P = .52$, $I^2 = 0\%$).

The quality of evidence was rated down because of the retrospective study design of the source studies, publication bias, small sample sizes, and imprecision because of a very low incidence of implantation metastasis. Further, 1 study had an outsized impact on the forest plot because of a relatively higher incidence of metastasis within a small cohort.¹¹ These data were considered outliers and led to further down-rating of the quality of evidence.

Because a transcutaneous direct PEG obviates the transoral passage of the feeding tube, it has historically been considered to have a lower risk of implantation metastasis in patients with malignant dysphagia. A transcutaneous direct PEG can also be performed using a narrow-caliber or ultraslim gastroscope⁷⁷ in patients with esophageal cancer with luminal stenosis or complex strictures. Hence, it is considered an attractive alternative to a conventional pull PEG or an IR-G, although the 5F catheters used for IR-G are also often able to navigate tight malignant strictures.

One study compared transcutaneous direct PEG and IR-G in patients unable to undergo a transoral pull PEG. This single-center, nonrandomized study noted comparable technical success between transcutaneous direct PEG and IR-G.⁴ However, the all-cause 30-day mortality rate was 15.6% (7/45) in IR-G compared with 0 for transcutaneous direct PEG. The only serious adverse outcome, a perforation of the colon, was noted with IR-G. Procedure times were shorter and dosage of sedatives higher with transcutaneous direct PEG compared with IR-G.

No studies assessed cost and cost-effectiveness. In view of the inconsistency, imprecision, small sample sizes, and retrospective study design of the source studies, the evidence was rated down to very low quality.

Discussion

In addition to concerns with the quality of the data, we noted that mechanical translocation of malignant cells during transoral passage of the gastrostomy tube is not the only putative etiology of implantation metastasis. Available literature also suggests hematogenous spread of malignant cells leading to implantation metastasis.⁷⁸ Implantation metastasis has also been reported with transcutaneous direct PEG as well as IR-G even though there is no transoral passage of the feeding tube.^{79,80}

Further, the panel expressed significant concerns regarding the inequitable access to IR gastrostomy and transcutaneous direct PEG because most centers preferentially perform pull PEG.⁸¹ In many centers, the expertise to perform transcutaneous direct PEG is not available, and IR-G may be associated with adverse outcomes. Hence, although the use of transcutaneous direct PEG may be advisable, it is not mandatory, and the panel refrained from making a recommendation against use of transoral pull PEG in patients with aerodigestive malignancies despite such recommendations made by other gastroenterological societies.^{82,83}

The risk of implantation metastasis should be discussed with the patient during the informed consent process.⁸⁴ In centers where IR-G or transcutaneous direct PEG is available, these options should be offered. Further, the site of the gastrostomy should be periodically assessed for implantation metastasis during physical examination. Finally, better-quality studies examining implantation metastasis are needed to better delineate the risk of this outcome.

FUTURE DIRECTIONS

Our systematic literature review highlighted several areas in need of more data to inform the role of endoscopy in the management of PEG tubes. Future studies should address the following:

1. *Optimal gastrostomy technique for altered foregut anatomy.* Gastrostomy tubes can be placed surgically, fluoroscopically, or endoscopically.^{1,14} Further, endoscopic techniques include direct, push, and pull PEG. Although some comparative data exist, high-quality studies are needed to guide selection techniques that are tailored to specific clinical scenarios such as surgically altered foregut anatomy.
2. *Selection of type of feeding tube.* Feeding tubes come in various designs and sizes. These include standard-profile and low-profile tubes, tubes with bumper or balloon retention systems, and tubes with varying number of ports, including a dedicated port for medications. Studies examining the relative benefits and harms of the different types of tubes are needed to select the appropriate feeding tube tailored to specific patient needs.
3. *Protocols for exchange of feeding tube.* Feeding tubes are often placed for long-term access and hence require periodic exchange. Evidence-based recommendations are not available because of a lack of high-quality studies that can define the protocols for scheduled exchanges of feeding tubes.
4. *Safety of PEG tubes in patients with ascites.* A subset of patients needing enteral access have ascites, which could be because of portal hypertension, peritoneal metastasis from abdominal and pelvic malignancies, or poor nutritional status. Adverse events include bacterial peritonitis, failure of tract maturation, and consequent leakage of peritoneal fluid in the event of PEG removal. Although some data suggest a higher incidence of adverse events in hospitalized patients with ascites,^{85,86} other studies suggest gastrostomy tubes for venting are safe in patients with malignant ascites.^{87,88} Although PEG tube placement may be safe in malignant ascites especially after a therapeutic paracentesis, risks are higher with portal hypertension associated with cirrhosis. High-quality studies are needed to define the best practices and selection protocols in patients with ascites needing a PEG tube.
5. *Assessment of risk of implantation metastasis.* As noted above, there is a low but finite risk of implantation metastasis associated with PEG tubes, including the pull technique.⁶⁷ Although there are suggestions to avoid pull PEG in patients with foregut malignancies,^{82,83} better studies are needed to understand the risk of implantation metastasis and efficacy of endoscopic techniques to mitigate this risk.
6. *Managing long-term adverse events.* Potential postprocedure adverse events include leaking around the gastrostomy tube, cellulitis, persistent gastrocutaneous

fistula after removal of the feeding tube, or pain at the gastrostomy site. Research is needed to find algorithmic solutions to these common long-term issues.

7. *Developing an algorithm for gastric, gastro-jejunal, or jejunal access.* Subsets of patients may benefit from postpyloric feeding, with or without concurrent gastric access. These include patients with malignant gastric outlet obstruction or selected patients with medication-refractory gastroparesis. Comparing clinical outcomes and assessing best practices to identify patients who would benefit from a transgastric jejunal access versus direct jejunal access need to be undertaken.

SUMMARY AND CONCLUSIONS

These ASGE guidelines use the best available evidence to make recommendations on the management of PEG tubes. In patients needing enteral access, the ASGE suggests PEG as the initial intervention while continuing antiplatelet medications and recommends starting tube feeding within 4 hours of placement. Management of anticoagulant medications should be individualized as part of a shared medical decision-making based on a multidisciplinary discussion regarding the risk of bleeding versus cardiovascular events. In patients with malignant dysphagia, either transoral pull PEG or direct PEG can be performed for initial enteral access.

GUIDELINE UPDATE

ASGE guidelines are reviewed for updates approximately every 5 years or if new data may influence a recommendation. Updates follow the same ASGE guideline development process.

DISCLOSURE

The following authors disclosed financial relationships: D. R. Kohli: Consultant for and research support from Olympus Corporation of the Americas. W. M. Abidi: Consultant for Ambu Inc, Apollo Endosurgery US Inc, and Conmed Corporation; research support from GI Dynamics; food and beverage compensation from Ambu Inc, Apollo Endosurgery US Inc, Conmed Corporation, Olympus America Inc, AbbVie Inc, Boston Scientific Corporation, RedHill Biopharma Inc, and Salix Pharmaceuticals. N. Cosgrove: Consultant for Olympus Corporation of the Americas and Boston Scientific Corporation; food and beverage compensation from Boston Scientific Corporation and Ambu Inc. J. D. Machicado: Consultant for Mauna Kea Technologies, Inc; food and beverage compensation from Mauna Kea Technologies, Inc and Boston Scientific Corporation. N. Forbes: Consultant for Boston Scientific Corporation, Pentax of America, Inc, AstraZeneca, and Pendopharm Inc; speaker for Pentax of

America, Inc and Boston Scientific Corporation; research support from Pentax of America, Inc. N. B. Marya: Consultant for Boston Scientific Corporation; food and beverage compensation from Boston Scientific Corporation and Apollo Endosurgery US Inc. N. R. Thiruvengadam: Research support from Boston Scientific Corporation. N. C. Thosani: Consultant for Pentax of America, Inc, Boston Scientific Corporation, and Ambu Inc; travel compensation and food and beverage compensation from Pentax of America, Inc, Boston Scientific Corporation, and AbbVie Inc; speaker for AbbVie Inc. S. Ngamruengphong: Consultant for Boston Scientific Corporation; food and beverage compensation from Medtronic, Inc, Boston Scientific Corporation, Pentax of America, Inc, and Ambu Inc. S. E. Elhanafi: Food and beverage compensation from Medtronic, Inc, Nestle HealthCare Nutrition Inc, Ambu Inc, Salix Pharmaceuticals, Takeda Pharmaceuticals USA, Inc, and Merit Medical Systems Inc. S. G. Sheth: Consultant for Janssen Research & Development, LLC. S. A. McClave: Consultant for Nestle; speaker for Nestle and Abbott; advisory board for Avanos. B. J. Qumseya: Consultant for Medtronic, Inc and Assertio Management, LLC; food and beverage compensation from Medtronic, Inc, Fujifilm Healthcare Americas Corporation, and Boston Scientific Corporation; speaker for Castle Biosciences. All other authors disclosed no financial relationships.

ACKNOWLEDGMENTS

We thank Leonard Amato and Aaron Zelin, patient representatives from the National Foundation of Swallowing Disorders, for participating in our panel as well as Drs Michael Bartel, Hala Fatima, and Kevin Waschke for their review of this document. This guideline was funded exclusively by the American Society for Gastrointestinal Endoscopy; no outside funding was received to support the development of this guideline.

REFERENCES

1. ASGE Technology Committee; Kwon RS, Banerjee S, Desilets D, et al. Enteral nutrition access devices. *Gastrointest Endosc* 2010;72:236-48.
2. Arvanitakis M, Gkolfakis P, Despott EJ, et al. Endoscopic management of enteral tubes in adult patients—part 1: definitions and indications. *European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy* 2021;53:81-92.
3. ASGE Standards of Practice Committee; Coelho-Prabhu N, Forbes N, Thosani NC, et al. Adverse events associated with EGD and EGD-related techniques. *Gastrointest Endosc* 2022;96:389-401.
4. Kohli DR, Smith C, Chaudhry O, et al. Direct percutaneous endoscopic gastrostomy versus radiological gastrostomy in patients unable to undergo transoral endoscopic pull gastrostomy. *Dig Dis Sci* 2023;68:852-9.
5. ASGE Standards of Practice Committee; Acosta RD, Abraham NS, Chandrasekhara V, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. *Gastrointest Endosc* 2016;83:3-16.
6. Thosani N, Rashtak S, Kannadath BS, et al. Bleeding risk and mortality associated with uninterrupted antithrombotic therapy during

- percutaneous endoscopic gastrostomy tube placement. *Am J Gastroenterol* 2021;116:1868-75.
7. Schünemann H, Brożek J, Guyatt G, et al, editors. GRADE handbook for grading quality of evidence and strength of recommendations updated October 2013: the GRADE Working Group; 2013 Available at: <https://gdt.gradepro.org/app/handbook/handbook.html>. Accessed January 30, 2022.
 8. Kohli DR, Amateau SK, Desai M, et al. American Society for Gastrointestinal Endoscopy guideline on management of post-liver transplant biliary strictures: summary and recommendations. *Gastrointest Endosc* 2023;97:607-14.
 9. Standards of Practice Committee; Amateau SK, Kohli DR, Desai M, et al. American Society for Gastrointestinal Endoscopy guideline on management of post-liver transplant biliary strictures: methodology and review of evidence. *Gastrointest Endosc* 2023;97:615-37.
 10. Kohli DR, Radadiya DK, Patel H, et al. Comparative outcomes of endoscopic and radiologic gastrostomy tube placement: a systematic review and meta-analysis with GRADE analysis. *Ann Gastroenterol* 2022;35:592-602.
 11. Forner D, Mok F, Verma N, et al. Placement technique impacts gastrostomy tube-related complications amongst head and neck cancer patients. *Oral Oncol* 2022;130:105903.
 12. Mohamed Elfadi O, Linch FB, Seegmiller SL, et al. Safety and effectiveness of radiologic and endoscopic percutaneous gastrostomy placement: a randomized study. *JPEN J Parenter Enteral Nutr* 2022;46:1808-17.
 13. Kohli DR, Kennedy KF, Desai M, et al. Comparative safety of endoscopic vs radiologic gastrostomy tube placement: outcomes from a large, nationwide veterans affairs database. *Am J Gastroenterol* 2021;116:2367-73.
 14. Kohli DR, Kennedy KF, Desai M, et al. Safety of endoscopic gastrostomy tube placement compared with radiologic or surgical gastrostomy: nationwide inpatient assessment. *Gastrointest Endosc* 2021;93:1077-85.e1.
 15. Maasarani S, Khalid SI, Creighton C, et al. Outcomes following percutaneous endoscopic gastrostomy versus fluoroscopic procedures in the Medicare population. *Surg Open Sci* 2021;3:2-7.
 16. Allen JA, Chen R, Ajroud-Driss S, et al. Gastrostomy tube placement by endoscopy versus radiologic methods in patients with ALS: a retrospective study of complications and outcome. *Amyotroph Lateral Scler Frontotemp Degen* 2013;14:308-14.
 17. Blondet A, Lebigot J, Nicolas G, et al. Radiologic versus endoscopic placement of percutaneous gastrostomy in amyotrophic lateral sclerosis: multivariate analysis of tolerance, efficacy, and survival. *J Vasc Interv Radiol* 2010;21:527-33.
 18. Cherian P, Blake C, Appleyard M, et al. Outcomes of radiologically inserted gastrostomy versus percutaneous endoscopic gastrostomy. *J Med Imaging Radiat Oncol* 2019;63:610-6.
 19. Desport JC, Mabrouk T, Bouillet P, et al. Complications and survival following radiologically and endoscopically-guided gastrostomy in patients with amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2005;6:88-93.
 20. Elliott LA, Sheridan MB, Denyer M, et al. PEG—Is the E necessary? A comparison of percutaneous and endoscopic gastrostomy. *Clin Radiol* 1996;51:341-4.
 21. Galaski A, Peng WW, Ellis M, et al. Gastrostomy tube placement by radiological versus endoscopic methods in an acute care setting: a retrospective review of frequency, indications, complications and outcomes. *Can J Gastroenterol* 2009;23:109-14.
 22. Laskaratos FM, Walker M, Walker M, et al. Predictive factors for early mortality after percutaneous endoscopic and radiologically-inserted gastrostomy. *Dig Dis Sci* 2013;58:3558-65.
 23. McAllister P, MacIver C, Wales C, et al. Gastrostomy insertion in head and neck cancer patients: a 3 year review of insertion method and complication rates. *Br J Oral Maxillofac Surg* 2013;51:714-8.
 24. Neeff M, Crowder VL, McIvor NP, et al. Comparison of the use of endoscopic and radiologic gastrostomy in a single head and neck cancer unit. *Austr N Z J Surg* 2003;73:590-3.
 25. Pruthi D, Duerksen DR, Singh H. The practice of gastrostomy tube placement across a Canadian regional health authority. *Am J Gastroenterol* 2010;105:1541-50.
 26. Rio A, Ellis C, Shaw C, et al. Nutritional factors associated with survival following enteral tube feeding in patients with motor neurone disease. *J Hum Nutr Diet* 2010;23:408-15.
 27. Rustom IK, Jebreel A, Tayyab M, et al. Percutaneous endoscopic, radiological and surgical gastrostomy tubes: a comparison study in head and neck cancer patients. *J Laryngol Otol* 2006;120:463-6.
 28. Silas AM, Pearce LF, Lestina LS, et al. Percutaneous radiologic gastrostomy versus percutaneous endoscopic gastrostomy: a comparison of indications, complications and outcomes in 370 patients. *Eur J Radiol* 2005;56:84-90.
 29. Vidhya C, Phoebe D, Dhina C, et al. Percutaneous endoscopic gastrostomy (PEG) versus radiologically inserted gastrostomy (RIG): a comparison of outcomes at an Australian teaching hospital. *Clin Nutr ESPEN* 2018;23:136-40.
 30. Wollman B, D'Agostino HB. Percutaneous radiologic and endoscopic gastrostomy: a 3-year institutional analysis of procedure performance. *AJR Am J Roentgenol* 1997;169:1551-3.
 31. Chiò A, Galletti R, Finocchiaro C, et al. Percutaneous radiologic gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. *J Neurol Neurosurg Psychiatry* 2004;75:645-7.
 32. La Nauze RJ, Collins K, Lyon S, et al. Outcomes of percutaneous endoscopic gastrostomy versus radiologically inserted gastrostomy tube insertion at a tertiary hospital. *e-SPEN J* 2012;7:e144-8.
 33. ProGas Study Group. Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. *Lancet Neurol* 2015;14:702-9.
 34. Möller P, Lindberg CG, Zilling T. Gastrostomy by various techniques: evaluation of indications, outcome, and complications. *Scand J Gastroenterol* 1999;34:1050-4.
 35. Clayton S, DeClue C, Lewis T, et al. Radiologic versus endoscopic placement of gastrostomy tube: comparison of indications and outcomes at a tertiary referral center. *South Med J* 2019;112:39-44.
 36. Cosentini EP, Sautner T, Gnant M, et al. Outcomes of surgical, percutaneous endoscopic, and percutaneous radiologic gastrostomies. *Arch Surg* 1998;133:1076-83.
 37. Grant DG, Bradley PT, Pothier DD, et al. Complications following gastrostomy tube insertion in patients with head and neck cancer: a prospective multi-institution study, systematic review and meta-analysis. *Clin Otolaryngol* 2009;34:103-12.
 38. Laasch HU, Wilbraham L, Bullen K, et al. Gastrostomy insertion: comparing the options—PEG, RIG or PIG? *Clin Radiol* 2003;58:398-405.
 39. MacLean AA, Alvarez NR, Davies JD, et al. Complications of percutaneous endoscopic and fluoroscopic gastrostomy tube insertion procedures in 378 patients. *Gastroenterol Nurs* 2007;30:337-41.
 40. Park SK, Kim JY, Koh SJ, et al. Complications of percutaneous endoscopic and radiologic gastrostomy tube insertion: a KASID (Korean Association for the Study of Intestinal Diseases) study. *Surg Endosc* 2019;33:750-6.
 41. Righetti J, Morris S, Fotoohi M, et al. Is percutaneous radiologic gastrostomy safer than percutaneous endoscopic gastrostomy? *Am J Interv Radiol* 2021;5:1-6.
 42. Singh RR, Nah SA, Roebuck DJ, et al. Double-blind randomized clinical trial of percutaneous endoscopic gastrostomy versus radiologically inserted gastrostomy in children. *Br J Surg* 2017;104:1620-7.
 43. Thornton FJ, Fotheringham T, Alexander M, et al. Amyotrophic lateral sclerosis: enteral nutrition provision—endoscopic or radiologic gastrostomy? *Radiology* 2002;224:713-7.
 44. Barkmeier JM, Trerotola SO, Wiebke EA, et al. Percutaneous radiologic, surgical endoscopic, and percutaneous endoscopic gastrostomy/gastrojejunostomy: comparative study and cost analysis. *Cardiovasc Interv Radiol* 1998;21:324-8.
 45. Westaby D, Young A, O'Toole P, et al. The provision of a percutaneously placed enteral tube feeding service. *Gut* 2010;59:1592-605.

46. ASGE Standards of Practice Committee; Khashab MA, Chithadi KV, Acosta RD, et al. Antibiotic prophylaxis for GI endoscopy. *Gastrointest Endosc* 2015;81:81-9.
47. Chehab MA, Thakor AS, Tulin-Silver S, et al. Adult and pediatric antibiotic prophylaxis during vascular and IR procedures: a Society of Interventional Radiology practice parameter update endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology. *J Vasc Interv Radiol* 2018;29:1483-501.
48. Jain NK, Larson DE, Schroeder KW, et al. Antibiotic prophylaxis for percutaneous endoscopic gastrostomy. A prospective, randomized, double-blind clinical trial. *Ann Intern Med* 1987;107:824-8.
49. Lee C, Im JP, Kim JW, et al. Risk factors for complications and mortality of percutaneous endoscopic gastrostomy: a multicenter, retrospective study. *Surg Endosc* 2013;27:3806-15.
50. Singh D, Laya AS, Vaidya OU, et al. Risk of bleeding after percutaneous endoscopic gastrostomy (PEG). *Dig Dis Sci* 2012;57:973-80.
51. Richter-Schrag HJ, Richter S, Ruthmann O, et al. Risk factors and complications following percutaneous endoscopic gastrostomy: a case series of 1041 patients. *Can J Gastroenterol* 2011;25:201-6.
52. Patel H, Gaduputi V, Sakam S, et al. Serotonin reuptake inhibitors and post-gastrostomy bleeding: reevaluating the link. *Ther Clin Risk Manag* 2015;11:1283-9.
53. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. *Arch Intern Med* 2008;168:63-9.
54. Stein J, Schulte-Bockholt A, Sabin M, et al. A randomized prospective trial of immediate vs. next-day feeding after percutaneous endoscopic gastrostomy in intensive care patients. *Intensive Care Med* 2002;28:1656-60.
55. McCarter TL, Condon SC, Aguilar RC, et al. Randomized prospective trial of early versus delayed feeding after percutaneous endoscopic gastrostomy placement. *Am J Gastroenterol* 1998;93:419-21.
56. Choudhry U, Barde CJ, Markert R, et al. Percutaneous endoscopic gastrostomy: a randomized prospective comparison of early and delayed feeding. *Gastrointest Endosc* 1996;44:164-7.
57. Brown DN, Miedema BW, King PD, et al. Safety of early feeding after percutaneous endoscopic gastrostomy. *J Clin Gastroenterol* 1995;21:330-1.
58. Shahmanyan D, Lawrence JC, Lollar DI, et al. Early feeding after percutaneous endoscopic gastrostomy tube placement in patients who require trauma and surgical intensive care: a retrospective cohort study. *JPEN J Parenter Enteral Nutr* 2022;46:1160-6.
59. Cobell WJ, Hinds AM, Nayani R, et al. Feeding after percutaneous endoscopic gastrostomy: experience of early versus delayed feeding. *South Med J* 2014;107:308-11.
60. Lamb LC, Jayaraman V, Montgomery SC, et al. Immediate tube feeding after percutaneous endoscopic gastrostomy: early return to goal tube feeds without added complications. *Conn Med* 2017;81:75-9.
61. Vyawahare MA, Shirodkar M, Gharat A, et al. A comparative observational study of early versus delayed feeding after percutaneous endoscopic gastrostomy. *Indian J Gastroenterol* 2013;32:366-8.
62. Wang Z, Ding W, Fang Q, et al. Effects of not monitoring gastric residual volume in intensive care patients: a meta-analysis. *Int J Nurs Stud* 2019;91:86-93.
63. Yasuda H, Kondo N, Yamamoto R, et al. Monitoring of gastric residual volume during enteral nutrition. *Cochrane Database Syst Rev* 2021;9:CD013335.
64. Reigner J, Mercier E, Le Gouge A, et al. Effect of not monitoring residual gastric volume on risk of ventilator-associated pneumonia in adults receiving mechanical ventilation and early enteral feeding: a randomized controlled trial. *JAMA* 2013;309:249-56.
65. Montejo JC, Miñambres E, Bordejé L, et al. Gastric residual volume during enteral nutrition in ICU patients: the REGANE study. *Intensive Care Med* 2010;36:1386-93.
66. Wiese AN, Rogers MJ, Way M, et al. The impact of removing gastric residual volume monitoring and enteral nutrition rate titration in adults receiving mechanical ventilation. *Aust Crit Care* 2020;33:155-61.
67. Siu J, Fuller K, Nadler A, et al. Metastasis to gastrostomy sites from upper aerodigestive tract malignancies: a systematic review and meta-analysis. *Gastrointest Endosc* 2020;91:1005-14.
68. Akkersdijk WL, van Bergeijk JD, van Egmond T, et al. Percutaneous endoscopic gastrostomy (PEG): comparison of push and pull methods and evaluation of antibiotic prophylaxis. *Endoscopy* 1995;27:313-6.
69. Retes FA, Kawaguti FS, de Lima MS, et al. Comparison of the pull and introducer percutaneous endoscopic gastrostomy techniques in patients with head and neck cancer. *United Eur Gastroenterol J* 2017;5:365-73.
70. Ehrsson YT, Langius-Eklöf A, Bark T, et al. Percutaneous endoscopic gastrostomy (PEG)—a long-term follow-up study in head and neck cancer patients. *Clin Otolaryngol Allied Sci* 2004;29:740-6.
71. Hiki N, Maetani I, Suzuki Y, et al. Reduced risk of peristomal infection of direct percutaneous endoscopic gastrostomy in cancer patients: comparison with the pull percutaneous endoscopic gastrostomy procedure. *J Am Coll Surg* 2008;207:737-44.
72. Köhler G, Kalcher V, Koch OO, et al. Comparison of 231 patients receiving either “pull-through” or “push” percutaneous endoscopic gastrostomy. *Surg Endosc* 2015;29:170-5.
73. Teich N, Selig L, Liese S, et al. Usage characteristics and adverse event rates of the direct puncture and pull techniques for percutaneous endoscopic gastrostomy in patients with malignant tumors of the upper aerodigestive tract. *Endosc Int Open* 2018;6:E29-35.
74. Walton GM. Complications of percutaneous gastrostomy in patients with head and neck cancer—an analysis of 42 consecutive patients. *Ann R Coll Surg Engl* 1999;81:272-6.
75. Yang Y, Schneider J, Düber C, et al. Comparison of fluoroscopy-guided pull-type percutaneous radiological gastrostomy (pull-type-PRG) with conventional percutaneous radiological gastrostomy (push-type-PRG): clinical results in 253 patients. *Eur Radiol* 2011;21:2354-61.
76. Strijbos D, Keszthelyi D, Gilissen LPL, et al. Percutaneous endoscopic versus radiologic gastrostomy for enteral feeding: a retrospective analysis on outcomes and complications. *Endosc Int Open* 2019;07:E1487-95.
77. Kohli DR, Baillie J. How endoscopes work. In: Chandrasekhara V, Elmunzer BJ, Khashab MA, et al, editors. *Clinical gastrointestinal endoscopy*. 3rd ed. Elsevier: Philadelphia, PA: 2019. p. 24-31.
78. Otsuka I. Cutaneous metastasis after surgery, injury, lymphadenopathy, and peritonitis: possible mechanisms. *Int J Mol Sci* 2019;20:3286.
79. Francesca V, Giuseppina DC, Federica G, et al. Risk of tumor implantation in percutaneous endoscopic gastrostomy in the upper aerodigestive tumors. *Acta Biomed* 2018;89(Suppl 8):117-21.
80. Rowell NP. Tumor implantation following percutaneous endoscopic gastrostomy insertion for head and neck and oesophageal cancer: review of the literature. *Head Neck* 2019;41:2007-15.
81. ASGE Training Committee; Enestvedt BK, Jorgensen J, Sedlack RE, et al. Endoscopic approaches to enteral feeding and nutrition core curriculum. *Gastrointest Endosc* 2014;80:34-41.
82. Gkolfakis P, Arvanitakis M, Despott EJ, et al. Endoscopic management of enteral tubes in adult patients—part 2: peri- and post-procedural management. *European Society of Gastrointestinal Endoscopy (ESGE) guideline*. *Endoscopy* 2021;53:178-95.
83. Gleeson FC, Lee JH, Dewitt JM. Tumor seeding associated with selected gastrointestinal endoscopic interventions. *Clin Gastroenterol Hepatol* 2018;16:1385-8.
84. ASGE Standards of Practice Committee; Storm AC, Fishman DS, Buxbaum JL, et al. American Society for Gastrointestinal Endoscopy guideline on informed consent for GI endoscopic procedures. *Gastrointest Endosc* 2022;95:207-15.
85. Shah I, Bhurwal A, Mehta H, et al. Trends and outcomes of percutaneous endoscopic gastrostomy in hospitalized patients with malignant and nonmalignant ascites: a nationwide population study. *Ann Gastroenterol* 2020;33:656-60.

86. Baltz JG, Argo CK, Al-Osaimi AMS, et al. Mortality after percutaneous endoscopic gastrostomy in patients with cirrhosis: a case series. *Gastrointest Endosc* 2010;72:1072-5.
87. Shaw C, Bassett RL, Fox PS, et al. Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites. *Ann Surg Oncol* 2013;20:497-505.
88. Issaka RB, Shapiro DM, Parikh ND, et al. Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction. *Surg Endosc* 2014;28:1668-73.

Abbreviations: ASGE, American Society for Gastrointestinal Endoscopy; CI, confidence interval; GRADE, Grading of Recommendations Assessment, Development and Evaluation; IR-G, interventional radiology-guided gastrostomy; OR, odds ratio; RCT, randomized controlled trial; RR, relative risk.

*Drs Kohli, Abidi, and Cosgrove contributed equally to this article.



Use your mobile device to scan this QR code and watch the author interview. Download a free QR code scanner by searching “QR Scanner” in your mobile device’s app store.

Copyright © 2025 by the American Society for Gastrointestinal Endoscopy
0016-5107/\$36.00
<https://doi.org/10.1016/j.gie.2024.08.044>

Received August 21, 2024. Accepted August 23, 2024.

Current affiliations: Pancreas and Liver Clinic, Providence Sacred Medical Center, Elson Floyd School of Medicine, Washington State University, Spokane, Washington, USA (1), Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA (2), Center for Interventional Endoscopy AdventHealth, Orlando, Florida, USA (3), Division of Gastroenterology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA (4), Center for Interventional Gastroenterology at UTHealth (5), Department of Diagnostic and Interventional Radiology at UTHealth (16), McGovern Medical School, Houston, Texas, USA; Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada (6), Division of Gastroenterology, UMass Chan Medical School, Worcester, Massachusetts, USA (7), Division of Gastroenterology and Hepatology, Loma Linda University, Loma Linda, California, USA (8), Division of Gastroenterology, University of Washington Medical Center, Seattle, Washington, USA (9), Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland, USA (10), Division of Gastroenterology, Texas Tech University Health Sciences Center, El Paso, Texas, USA (11), Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA (12), Division of Pediatric Gastroenterology, Hepatology and Nutrition, Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas, USA (13), Division of Gastroenterology, Hepatology and Nutrition, University of Utah, Salt Lake City, Utah, USA (14), Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA (15), Department of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, Florida, USA (17), Department of Pharmacy, UF Health Shands Hospital, University of Florida College of Pharmacy, Gainesville, Florida, USA (18).

Reprint requests: Bashar J. Qumseya, MD, MPH, FASGE, Department of Gastroenterology, Hepatology and Nutrition, University of Florida, PO Box 100214, 1329 SW 16th St, Ste 5251, Gainesville, FL 32610-0214.